Despite intensive antibiotic treatment, Pseudomonas aeruginosa often persists in the airways 36 of cystic fibrosis (CF) patients for decades, and can do so without antibiotic resistance 37 development. Using high-throughput screening assays of bacterial survival after treatment with 38 high concentrations of ciprofloxacin and tobramycin, we have determined the prevalence of 39 persisters in a large patient cohort consisting of 460 longitudinal isolates of P. aeruginosa from 40 39 CF patients. Thirty patients exhibited high persister variants (Hip, defined by survival of at 41 least 75% of replicates) in at least one of the two antibiotic screens (25% of isolates in total). 42
Introduction 69
Antibiotic-tolerant persister cells are suspected to be a significant clinical problem that has 70 been seriously neglected in favor of combating antibiotic-resistant bacteria, though persisters 71 were in fact described shortly after the clinical introduction of antibiotics (1). Persisters are 72 distinct from antibiotic-resistant mutants, as they do not grow in the presence of antibiotics. 73 Instead, they remain dormant during antibiotic exposure but retain the capacity to resuscitate 74 and restore the population when antibiotic concentrations drop (2-4). However, our 75 understanding of the physiology and clinical relevance of persister cells is limited, given the 76 difficulty in reliably isolating what is theorized to be a stochastic phenotype in vitro, much less 77 monitoring this phenotype in routine clinical care. Thus, while a few characterizations of small 78 environmental isolate collections have shown that formation of persisters varies across strains 79 (5, 6), few studies have assayed persister formation in clinical or other complex environmental 80 scenarios. One study of oral carriage (0-19 weeks) of Candida albicans isolates from 22 cancer 81 patients undergoing chemotherapy found that patients with carriage of greater than 8 weeks 82 had significantly higher persister levels than those with less than 8 weeks of carriage, but did 83 not address the underlying mechanisms of persistence in this pathogen (7) . To examine the 84 underpinnings and long-term impact of the persister phenotype in a clinical scenario, both a 85 large, aligned patient cohort that places the bacteria under similar environmental stresses as 86 well as isolate sampling at a resolution that captures the emergence and longevity of the 87 phenotype are needed. 88
Results 137
The isolate collection 138
We examined a collection of 460 P. aeruginosa airway isolates obtained from 39 young CF 139 patients over a 10 year period while they were treated at the Copenhagen CF Centre at 140 Rigshospitalet (22) . These patients represent a cohort aligned at the early infection stage and 141 undergoing similar treatment regimens per CF Centre guidelines, with repeated culture of P. 142 aeruginosa from their monthly sputum sampling within a time frame of 2-10 years (patient 143 inclusion was on a rolling basis over the study period in order to capture all early colonization 144 cases). Early isolates therefore represent bacteria that have not been exposed to substantial 145 antibiotic treatment before the study start excepting rare cases of strain transmission from 146 another patient. The bacterial CF isolates have been grouped into 52 genetically distinct clone 147 types (22), and while many patients retained a monoclonal infection during the entire course 148 of infection, half (n=20, 51.3 %) were infected at least transiently with another clone type. To 149 effectively account for these multi-clonal infections, clinical isolates are described by their 150 patient-specific lineage combining the clone type and the patient of origin (74 lineages in total). 151
Throughout this paper, we will also refer to 'Time since first detection' for each isolate, which 152 represents the length of time between first detection and subsequent isolations of the same 153 patient-specific lineage. 154 155
Identification of high persister (Hip) isolates by high-throughput screening 156
We screened the collection of P. aeruginosa isolates for the propensity to survive in the 157 presence of high concentrations of antibiotics. We chose two distinct antibiotics that matched 158 the following criteria; (i) they are frequently used to treat early P. aeruginosa infections in CF 159 patients; (ii) have contrasting targets and mechanisms of action; (iii) drive resistance 160 development with different dynamics in patients; and (iv) are each bactericidal toward 161 stationary phase P. aeruginosa (23, 24) . On this basis, we performed two independent screens 162 using either the fluoroquinolone ciprofloxacin, which interacts with DNA gyrase, or the 163 aminoglycoside tobramycin, which acts upon bacterial ribosomes. Briefly, P. aeruginosa 164 subcultures in micro-titer plates were grown for 48 hours until they reached stationary phase, 165 after which they were challenged with antibiotics (100 μg/ml) for 24 hours before survival was 166 assessed (Fig. 1A) . A standardised antibiotic concentration was used that was at least 25-times 167 higher than the European Committee on Antimicrobial Susceptibility Testing (EUCAST) 168 resistance breakpoint for each drug, minimising the chance that the screen selected for isolates 169 with modestly elevated minimum inhibitory concentrations (MICs). Within each antibiotic 170 6 screen, isolates were assayed eight times (technical quadruplicates performed in duplicate 171 biological experiments with a positive growth control for at least 3 of 4 replicates in each 172 experiment) and scored based on the capacity to re-grow after antibiotic treatment. An isolate 173 was given a score of 0 if it failed to re-grow in any replicate of an experiment, a score of 1 if it 174 grew once in both biological duplicates, a score of 2 if it grew in half of the technical replicates 175 in each experiment, a score of 3 if it grew in at least three replicates in each experiment, and a 176 score of 4 if it grew in all replicates (Fig. 1B , scores for the ciprofloxacin screen). To validate 177 our high-throughput screening approach, we selected 25 isolates, and enumerated CFUs 178 following 24 hours of ciprofloxacin treatment using standard survival assays. We observed a 179 significant positive correlation between persister score and CFU/ml following treatment (r2 180 0.5719, p < 0.0001, SI Appendix, Fig. S1 ), thus demonstrating the validity of our experimental 181 approach. 182 183 184
We defined high persister (Hip) isolates as those scoring either 3 or 4 (i.e. at least six of eight 185 technical replicates re-grew) and low persister (Lop) isolates as those scoring between 0 and 2. 186 This stringent scoring system was used to minimise the mis-classification of false Hips and 187 focus our analysis on isolates reliably producing persister cells, representing the most 188 concerning phenotype in a clinical environment. Isolates with a score of 4 made up the largest 189
Hip group, while the largest Lop group consisted of isolates scored as 0, failing to grow in any 190 replicate ( Fig 1B) . To validate this classification system, we selected six isolates from the same 191 patients, three of which were putative Hips, and three of which were classed as Lops and 192 performed time-dependent killing assays. The isolates displayed typical, biphasic killing (Fig. 193 1C). Each of the three putative Hip strains harboured a greater subpopulation of surviving 194 persister cells, thus they represent true Hips as defined by recent guidelines (25). In total, 195 24.8% of screened isolates (114 isolates) exhibited a persister phenotype in at least one of the 196 screens ( Fig. 1D , AnyHip dataset). In Figure 2 , we show the distribution of Hips across our 197 isolates with respect to (A) ciprofloxacin persistence (87 Cip Hip isolates), (B) tobramycin 198 persistence (60 Tob Hip isolates), and (C) multi-drug persistence (33 MD Hip isolates), where 199 an isolate scored 3 or more in both screens (Dataset 1). The bottom panel of Figure 2C shows 200 an explicit breakdown of dataset overlap. 201
202
The persister phenotype is antibiotic-specific and is dissociated from antibiotic resistance 203
As we were using antibiotics used in patient treatment to select for persister isolates, we 204 evaluated if we were simply selecting for resistant isolates as opposed to true Hips. 205
Ciprofloxacin and tobramycin MICs were determined using E-tests for isolates within the 206 collection. Most of the isolates were characterized as susceptible based on the EUCAST 207 breakpoints ( Fig. 2A, B ). Twenty-four ciprofloxacin susceptible isolates were Hip while 113 208
Lop variants were resistant. Similarly, 10 tobramycin resistant isolates were Lop while 50 Hip 209 isolates were tobramycin susceptible. We then contrasted the emergence of antibiotic resistance 210 versus Hip for all study lineages (Table S1 ). Of the 74 lineages assessed, resistance emerged 211 without Hip detection in 14 lineages (40%), while Hips emerged without resistance in 16 212 lineages. Resistance and persistence emerged simultaneously in 11 lineages. Resistance 213 preceded Hip in 9 lineages, while Hip preceded resistance in 5 lineages. If we used a less 214 stringent persister classification (persister score greater than 0 instead of 2), we observed that 215 resistance precedes persistence in 5 lineages, emerges simultaneously in 7 lineages, and follows 216 persistence in 15 lineages. Taken together, these data confirm that our screening approach 217 identified a persister phenotype separate from an antibiotic-resistant phenotype. 218
219
The persister phenotype is enriched in patient-specific lineages with slow-growing isolates 220
Along with changes in antibiotic susceptibility, the persister phenotype in our collection is not 221 arising in isolation from other adaptations. We and others have previously observed that CF 222 isolates adapt towards slow growth rates, increased resistance to antibiotics, and preference for 223 a biofilm lifestyle (18, 26, 27) . A specific association between slowing growth rate and the Hip 224 phenotype has also been proposed (28). To probe interrelationships with other phenotypes, we 225 used a principle component analysis to evaluate the distribution of Hip (blue diamonds) versus 226
Lop (grey circles) variants by multiple traits under selection pressure in the CF lung. We see 227
that Any Hip variants group with isolates exhibiting more adapted traits (increased antibiotic 228
MICs and slowing growth), but they also appear across the full phenotypic space alongside 229
Lop isolates (Fig. 3A) . 230 231 When comparing the ciprofloxacin versus tobramycin screen data ( Fig. 3B -C), the data ellipses 232 enclosing the approximated majority of each population (68% of the population, t distribution) 233
show that Hip variants (blue ellipse) only partially separate from Lop variants (grey ellipse). If 234 we assess the first Hip variant of each lineage (FirstHipblue ellipse with yellow fill), we see 235
FirstHips overlap substantially with both Lops and Hips. This variation of initial adaptive state 236 could be due to different adaptive trajectories with patients as well as lapses of time between 237
Hip emergence and isolation. The MD FirstHips show a more distinctive localization away 238 from Lops, which suggests further benefits of serious growth defects but could also be the 239 result of increased colonization time necessary to evolve both persister traits ( Fig. 3D ). If we 240 look at the likelihood of each lineage containing both Hips and slow growing isolates (where 241 the minimum growth rate of the lineage is less than 75% of the growth rate of PAO1), we see 242 a significant relationship between incidence of slow growing isolates and AnyHip isolates ( Sequencing and identification of genetic variations accumulating within each clone type have 250 been previously performed for most of the isolates used in this study (403 isolates, 46 lineages). 251
Genes targeted in convergent evolution were identified by the significant enrichment of 252 observed lineages with mutations in those genes compared to the number of lineages expected 253 to have mutations in the same genes according to genetic drift (derived from a simulated 254 evolution where lineages accumulate an equivalent number of mutations randomly for 1000 255 independent evolution simulations) (22). We split our dataset into Hip and Lop variants, and 256 then performed this same observed versus expected lineage enrichment analysis for each 257 population (see Materials and Methods for further details). The analysis was performed using 258 each of four datasets (ciprofloxacin Hip, tobramycin Hip, MD Hip and Any Hip), and the ratio 259 of lineage enrichment of mutated genes for Hip versus Lop variants allowed us to identify 260 candidate 'hip' genes for each set (Table 1 and Dataset 2). For completeness, we also performed 261 an additional genetic analysis focusing on mutations in non-coding sequences (Dataset 2). 262
263
In general, searching for hip genes accumulating non-synonymous mutations in Hip+ lineages 264 revealed only a weak signal for convergent evolution. Only one lineage assessed in the genetic 265 screen had only Hips present (the only isolate of the lineage assessed in our screen), so 266 practically all lineages with Hip isolates (Hip+ lineages, 29 included in the genetic study) also 267 contained Lops. Thus, mutated genes that were enriched 2-3 fold in independently evolved 268 Hip+ lineages were also frequently present in Lop isolates of the same lineage. Our lineage 269 enrichment ratio ultimately identified 12 mutated genes enriched in ciprofloxacin Hip+ 270 lineages (SI Appendix, Dataset 2), 13 mutated genes in tobramycin Hip+ lineages (SI 271 Appendix, Dataset 2), a solitary gene for MD Hip+ lineages (SI Appendix, Dataset 2), and 7 272 mutated genes for Any Hip+ lineages (Table 1) . 273 274 Of note, there was a surprising lack of the most prominent 'hip' genes previously identified in 275
in vitro studies and screens of P. aeruginosa (SI Appendix, Table S2 ). None of the lineage 276 enrichment data pointed toward RNA endonuclease-type toxin-antitoxin systems under 277 adaptive selection, which supports recent research that has questioned the contribution of these 278 systems to persistence in numerous bacterial pathogens (29-31). Instead, they belonged to 279 diverse functional categories including transcriptional regulation/two component regulatory 280 systems (4 genes), energy metabolism (3 genes), and DNA replication and repair (2 genes). In 281 the Any Hip analysis as well as the MD Hip analysis, the shared top gene target, aceF, encodes 282 a component of the pyruvate dehydrogenase complex, a key player in central metabolism, for 283 which functional mutations are known to reduce growth rate (32-34). Other genes in Table 1  284 include major regulators rpoN, known to induce a growth defect when functionally mutated 285 (35), and retS, which when functionally mutated induces an array of phenotypic changes linked 286 to chronic infection such as a non-motile biofilm lifestyle (36, 37). These genes, as well as 287 hypothetical protein PA4311, also overlap with the 'pathoadaptive' mutationally enriched gene 288 list identified in our prior study of convergent evolution across all lineages (22). 289 290
Hip variants emerge via diverse incidence patterns 291
The lack of strong genetic signatures differentiating Hip from Lop isolates motivated us to 292 examine the temporal dynamics of high persister incidence using our comprehensive Any Hip 293 dataset. In half of the patients, the earliest bacterial isolate is also the first-ever identified P. 294 aeruginosa in the clinic and the other patients' isolates also cover most of the initial 295 colonization phase. We can thus estimate the emergence of the Hip phenotype as P. aeruginosa 296 adapts from a wild type-similar naïve state into an adapted persistent pathogen. Previous 297 findings have indicated that the number of Hip variants from a lineage may increase over time 298
as the bacteria adapt to the antibiotic pressure in the host, and that once a Hip isolate is 299 observed, it is assumed to persist in the infecting population of the patient (7, 16). 300
301
To illustrate the range of persister dynamics we observe, we grouped each lineage by an array 302 of descriptors. The lineage descriptors include Hip presence versus absence (Hip+ vs Hip-), 303 transience of the lineage (whether it appears for less than 2 years, less than half the length of a 304 patient's infection and is afterwards replaced by another lineage), continuity of Hip variants 305 (whether Hips are present for at least 3 sampling dates in a row), dominance of Hip variants 306 (whether Hips make up at least 2/3 of all isolates of a lineage), and whether a Hip variant 307 initiates the lineage. Figure 4A shows the ordered distribution of the lineages in 10 different 308 groups based on descriptor sets, illustrating the diversity of lineage Hip dynamics. We see that: 4D). Thus, a given patient often has multiple infecting lineages, but the Hip-lineages are much 336 more likely to disappear over the course of infection. In summary, we find that despite variable 337 incidence patterns, a clear majority of patients are infected by Hip+ lineages, and these lineages 338 have a significant persistence advantage in comparison to Hip-lineages over time, suggesting 339 that the Hip phenotype contributes to a fitness increase in antibiotic-treated patients. 340 341
Hip variants show increased fitness in patient-similar biofilms 342
We next asked if Hip isolates are able to survive antibiotic treatment better than Lop isolates 343 with similar antibiotic susceptibilities and growth properties in more complex conditions. We 344 simulated antibiotic treatment of CF patients in a recently developed biofilm 345 Pharmacokinetic/Pharmacodynamic (PK/PD) system, in which the bacteria are challenged 346 with antibiotics in much the same way as in patients (38) . We chose this model because P. 347 aeruginosa often appears as biofilms in lungs of CF patients (39), because biofilms have been 348
shown to harbor increased levels of persister cells (40), and because our model mimics the 349 bacterial exposure to ciprofloxacin treatment as described for CF patients (38, 41). The isolates 350 that were chosen shared similar 1) time since their first detection in the CF lungs were similar, We have mapped the prevalence of persisters in a large, aligned cohort of patients under 370 intensive antibiotic treatment for a 10 year period (22, 41). Of 460 P. aeruginosa isolates from 371 the airways of 39 young CF patients (74 lineages in total), 24.8% of the isolates were scored 372 as robustly persisting Hip using a high-throughput screening approach to assay persistence 373 against ciprofloxacin or tobramycin ( Fig. 1 ). We show that the isolates display different levels 374 of persisters, in accordance with the variance previously found between species and within 375 strains (5, 43, 44). Most adaptive changes occur during the first few years of colonization (18, 376 45), which matches our objective of searching for signs of increased fitness of Hip variants in 377 patients treated continuously with antibiotics. We show that in a young CF patient cohort 378 impacted by early longitudinal colonization by P. aeruginosa strains, Hip variants were 379 sampled from 77% of the patients (N=30) during a 10-year observation window. Our analysis 380 is a new and important comparative baseline for developing effective surveillance, impact 381 assessment, and eventual control of the persister phenotype in the clinic. 382
383
In the early years of infection after first detection of P. aeruginosa clone types, the Hip 384 phenotype appeared and disappeared over time in our routine clinical sampling (Fig. 4A) . 385
While we see only partial overlap in Hip phenotype between our tobramycin and ciprofloxacin 386 screens, the number of lineages and patients that exhibit Hip variants increases over time for 387 all datasets ( Fig. 4B -C, SI Appendix, Fig. S2 ), suggesting a selective advantage of this 388 phenotype during the continuation of antibiotic therapy. In general, the majority of lineages 389 that showed short-term colonization were made up of only Lop variants, which may partly 390 explain why they were unable to establish a persistent infection (Fig. 4D) . These in-patient data 391 support the hypothesis that the Hip phenotype may generally have increased fitness in the 392 antibiotic-containing lung environment. It is, however, important to note that neither 393 dominance nor continuous presence of Hip variants is observed frequently (Fig. 4A ). It is likely 394 that fitness trade-offs and clonal interference impact on the fitness properties and the 395 persistence level of Hip variants (14). 396
397
Multiple relationships between the Hip phenotype and other phenotypic traits such as growth 398 rate and antibiotic resistance have been suggested in the literature. While some studies point 399 out that there is no correlation between the mean growth rates of isolates and the observed Hip 400 phenotype (46-48), reduced growth rates have been associated with high persister phenotypes 401 in E. coli (28). A recent study in Salmonella enterica further supports that slow growth 402 (regardless of mechanism) promotes the persister phenotype (31). We see that lineages which 403 produce isolates with reduced growth rate are significantly more likely to also produce Hips. 404 Furthermore, multiple genes targeted for mutation at a higher rate in Hip+ lineages are known 405 to induce a growth defect (Table 1 , SI Appendix, Dataset 2). However, we also observed the 406 Hip phenotype among naïve, fast growing clinical isolates of P. aeruginosa (Fig. 3) , supporting 407 that other factors also influence the phenotype. Drug-tolerant cells have also been proposed to 408 facilitate evolution of true antibiotic resistance in E. coli in vitro (49). Intermittent antibiotic 409 exposure of a batch culture of E. coli selected for mutant clones harboring tolerance mutations 410 that increased the growth lag-time, during which tolerance to killing by ampicillin selected for 411 MIC-increasing mutations. Though P. aeruginosa in the CF lung is also exposed to fluctuating 412 concentrations of antibiotic, our stringently defined Hip phenotype emerges simultaneously or 413 after resistance in a majority of cases in contrast to these findings. We also observe more or 414 less an equal number of lineages where Hip variants and resistant clones evolve independently 415 in patients under antibiotic selection pressure, which has previously been suggested by 416 comparative studies of lab strains (50). In summary, our results suggest that the Hip phenotype 417 may be an early advantageous adaptation (18) arising stochastically in infected patients treated 418 with antibiotics. 419 420 In many ways, investigations of the genetic underpinnings of persisters have been performed 421 analogously to studies of antibiotic resistance, i.e. it was expected that a relatively limited set 422 of genes defines the phenotype. In a study of urinary tract infection E. coli isolates, a gain-of-423 function mutation in the HipA toxin was commonly observed (21). In contrast, a lack of 424 common targeted genes in a small collection of clinical Hip strains of Mycobacterium 425 tuberculosis suggested utilization of multiple genetic pathways (51). Working at a much larger 426 collection scale in a faster adapting organism, we do not see enrichment of mutations which 427 previously have been associated with Hip phenotypes in vitro. A role for the top proposed 428 persister target aceF has yet to be described, likely owing to its important role in growth; 429 mutants with severe growth defects are often overlooked in genome-wide analyses in vitro. In 430 support of this, an aceF transposon mutant is not available from the widely used PAO1 two-431 allele mutant library, and aceF did not appear in a recent persister screen of a pool of 100,000 432 unique PAO1 transposon mutants (20, 52). The aceF gene is mutated in 20% of the Hip+ 433 lineages, which have been genotypically evaluated in our large, longitudinal collection, but in 434 three of six lineages, it is also mutated in Lops. Meanwhile, no other enriched mutated genes 435 are affected in as many Hip+ lineages alone (where only Hip isolates are affected). We 436 therefore conclude that a Hip phenotype may derive from a diverse array of accumulating 437 genetic changes, and it is likely that more than one mutation often determines the persister level 438 in the respective bacterial populations. There are certainly many adaptive routes to slowed 439 growth rate, which we have previously demonstrated is a convergent adaptive outcome in this 440 early isolate collection (18). Our results likely reflect the multiple and dynamic selection 441 pressures in vivo, which challenge Hip variants in antibiotic-treated populations very 442 differently than those assessed in steady state in vitro conditions with only one selective force. worthy of further study. It is also striking that the in vitro biofilm fitness assessment shows 455 efficient elimination of the Lop strain in the presence of ciprofloxacin, whereas Hip variants 456 often coexist with Lop variants in vivo (Fig. 4A ). This suggests that in the patient, direct 457 competition is likely limited by the large lung volume, many separate regional niches, and 458 influence of the host (55). 459
460
In summary, we have shown that Hip variants of P. aeruginosa emerge frequently in young 461 CF patients, and our results provide the first window into the evolving landscape of persistence 462 across a whole patient cohort. As pathogens increase their fitness in patients over time, they 463 clearly deploy the high persister phenotype as an important component in their survival 464 repertoire and can do so from the earliest stages of infection. It is still premature to conclude 465 that the high persister phenotype described here differs from what has been identified as Hip 466 in in vitro experimental conditions, but we consistently find a much broader bacterial repertoire 467 for survival in patient lungs. Hip variants do not seem to be mutated in genes previously found 468 from in vitro experiments to associate with Hip or in any strongly conserved genetic route. We 469 suggest that the difference in complexity of selection pressures when comparing in vitro and 470 in vivo environmental conditions results in highly different evolutionary trajectories. With our 471 investigation, we provide an important platform for broader clinically based studies and 472 contribute important new context for monitoring and one day hopefully preventing the high 473 persister phenotype in the clinic. 474
Materials and Methods 476
Strain collection. In total, we analyzed 460 P. aeruginosa airway isolates from young CF 477 patients followed at the Copenhagen CF-clinic at Rigshospitalet ( Plates were incubated statically for 48 hours at 37°C until the bacteria reached the stationary 504 phase of growth. To determine the initial viability of bacteria in each well, the replicator was 505 used to spot bacteria onto LB agar plates. Subsequently, 100 μg/ml of either ciprofloxacin or 506 tobramycin was added to each well and the microtiter plates were incubated statically for a 507 further 20-24 hours at 37°C. Serial dilutions were performed in 96 well microtiter plates 508 containing 0.9 % NaCl using an automated fluid handling robot (Viaflo3844/ Integra 509 Biosciences AG). Each dilution was spotted onto LB agar plates using the replicator and plates 510 were incubated at 37°C for at least 24 hours. The growth of the bacteria was compared by 511 counting colonies whenever possible and visually inspecting growth on the plates before and 512 after antibiotic treatment. Experiments were performed in duplicate for each antibiotic. 513 514 Persister assay validation. Time-kill experiments were performed for six isolates from the 515 same lineage (3 Hip and 3 Lop). P. aeruginosa were inoculated in 3 ml of LB media in 14 ml 516 culture tubes and incubated for 48 hours at 37°C with shaking at 250 rpm. Following 517 incubation, each culture was serially diluted using sterile 0.9 % NaCl, plated onto LB agar and 518 incubated at 37°C to determine the initial colony forming units (CFU). The remaining culture 519 was treated with 100 μg/ml of ciprofloxacin and incubated at 37°C with shaking. Cultures were 520 washed and diluted in sterile 0.9 % NaCl, then spot plated onto LB agar 6 and 24 hours after 521 the addition of antibiotic. Plates were incubated for 24 hours at 37°C. Bacteria survival was 522 measured by counting CFU per ml. For an additional 19 isolates, the same validation 523 experiment was performed, however cultures were only plated out after 24 hours, which was 524 within the 'persister plateau'. 525 526 Phenotype screening. The same frozen library of isolates used in the persister screening was 527 also replicated for assay of minimum inhibitory concentrations (MICs), bacterial growth, and 528 adhesion as described below and in Bartell et al (18) . MICs for ciprofloxacin and tobramycin 529 were determined using E-test methodology according to the manufacturer's recommendations 530 (Liofilchem®, Italy). To assay growth rate, bacteria were replicated from frozen plates into 531 96 well plates containing 150µL of LB medium, and incubated for 20 hours at 37°C with 532 constant shaking. OD 630 nm measurements were taken every 20 minutes using a microplate 533 reader (Holm & Halby, Copenhagen, Denmark/Synergy H1). Generation times (Td) were 534 determined on the best-fit line of a minimum of 3 points during exponential growth of the 535 bacterial isolate. Growth rates (hr-1) were calculated using the formula log (2)/ Td x 60 using 536 semi-automated code described in Bartell et al (18) . Adhesion was measured via attachment 537 assays in 96-well plates using NUNC peg lids and 96 well plates with 150µl Luria broth 538 medium. OD600nm was measured after incubation for 20 hours at 37°C and subsequently, a 539 "washing microtiter plate" with 180µl PBS was used to wash the peg lids and remove non-540 adhering cells. After transfer of the peg lids to a microtiter plate containing 160µl 0.01% 541 crystal violet (CV), they were left to stain for 15 min. To remove unbound crystal violet, the 542 lids were then washed again three times in three individual "washing microtiter plates" with 543 180µl PBS. Adhesion was measured by detaching adhering CV stained cells through washing 544 the peg lids in a microtiter plate containing 180µl 99% ethanol. An ELISA reader was then 545 used to measure the CV density at OD590nm. (Microtiter plates were bought at Fisher 546 Scientific, NUNC Cat no. 167008, peg lids cat no. 445497). 547
548
Pharmacokinetic/Pharmacodynamic (PK/PD) flow chamber biofilm model. For fitness 549 experiments, we used a PK/PD biofilm model system combined with confocal laser-scanning 550 microscopy. This system simulates the changing antibiotic concentrations in CF patients during 551
intravenous dosing in addition to retaining a similar profile of antibiotic decay as the one taking 552 place in CF patients (38). First, Hip and Lop isolates were differentially tagged with a yellow 553 fluorescent protein (YFP) or cyan fluorescent protein (CFP) respectively (14). Flow chambers 554 were inoculated with a 1:1 mixture of Hip and Lop bacteria (each isolate had an initial OD600 555 of 0.5). Bacteria were incubated for one hour at 30 °C, then nutrient flow was applied to each 556 chamber (40x diluted LB at a rate of 20 ml/h using a Watson Marlow 205S peristaltic pump). 557
Biofilms were allowed to form for 72 hours, at which point flow was stopped and medium 558 containing ciprofloxacin was added. Peak ciprofloxacin concentrations were calculated to be 4 559 mg/L based on PK parameters generated from healthy patients and CF patients (57). The 560 medium was pumped from the dilution flask through the antibiotic flask to the flow chambers 561 at a constant rate calculated to mimic the elimination rate constant of the antibiotic for 24 hrs. 562
A confocal laser-scanning microscope (Zeiss LSM 510) equipped with an argon/krypton laser 563 and detectors was used to monitor YFP (excitation 514 nm, emission 530 nm), CFP (excitation 564 458 nm, emission 490 nm), and dead cells (propidium iodine, excitation 543 nm, emission 565 565 nm). Multichannel simulated fluorescent projections (SFPs) and sections through the biofilms 566 were generated using Imaris software (Bitplane AG, Switzerland). The images were later 567 analyzed using COMSTAT (58). The PK/PD biofilm experiments were performed using two 568 independent Hip/Lop isolate pairs. Pairs were taken from the same patient at a similar time 569 since first detection and had similar growth rates and ciprofloxacin MICs (Table S2 ). The data 570 presented are from 2 biological experiments with 4 independent images taken from each 571 experiment. 572 573 Lineage-based genetic analysis. To generate a list of mutated genes associated with the Hip 574 phenotype, we used previously generated whole-genome sequencing data and variant calling 575 filtered to obtain nonsynonymous mutations that had accumulated within a lineage after the 576 first isolate (22) to evaluate differential mutation patterns for Lop and Hip variants for 403 577 sequenced isolates. In this filtering process, we also removed mutations associated with any 578 known 'hypermutator' isolates based on a mutation in mutS or mutL to avoid the influence of 579 high random mutation in these isolates on the analysis. To identify genes that were mutated 580 more than would have been expected by drift/random mutation while accounting for lineage-581 based mutation accumulation over time, we adapted a statistical analysis of the relative 582 mutation enrichment by lineage. After separating Lop and Hip variants, we compared the 583 mutated-gene lineage enrichment ratios for each group -the number of lineages with observed 584 mutation(s) in a given gene divided by the number of lineages expected to have mutations in 585 that gene according to random mutation. This enrichment metric was obtained as follows for 586 each group: we determined the observed number of lineages mutated (sum-obs) in each gene. 587
Then we estimated the average number of lineages (avg-exp) that would have been mutated in 588 each gene if mutations were spread out randomly over the PAO1 genome. Using a random-589 roulette algorithm, the number of genes that were observed to be mutated in a given lineage 590 was spread out over the PAO1 genome for 1000 iterations, providing a mgene by niteration matrix 591 of randomly mutated gene profiles for each lineage. For the same iteration n across all lineages, 592 it was noted whether a given gene was mutated. This allowed us to determine an average 593 number of lineages expected to be mutated over 1000 iterations. If a gene was hit by chance 594 more than once in a single iteration, this would still only be denoted as one hit; this is in 595 alignment with our observed mutation assessment, where multiple isolates could be hit in the 596 same gene but we only noted whether or not the lineage was hit by unique mutations in the 597 specific gene. After obtaining the relative enrichment by lineage, a Poisson distribution was 598 used to calculate the probability of the observed given random drift (expected). We also divided 599 the lineage enrichment metric for genes mutated in Hip variants by that for Lop variants to 600 obtain a lineage enrichment ratio to identify targeted genes particularly impactful in the 601 evolution of the Hip population. isolate tested 8 times in total). The screen was performed twice, using either ciprofloxacin or 835 tobramycin. Each isolate was treated with 100 g/ml of antibiotic for 24 hours, while growth 836 was assessed by plating on LB agar. Following antibiotic treatment, cultures were diluted then 837 plated on agar, at which point survival was assessed. Each isolate was given a persister score 838 based on consistent replicate survival following treatment. Isolates for which 3-4 replicates 839 survived for each BR were given a score of 3-4, respectively, and were considered high 840 persisters (Hip). Isolates with a respective score of 0-2 were considered low persisters (Lop). 841 'adapted' levels given the particular Hip dataset. We illustrate this using data ellipse enclosing 882 samples approximately within the first standard deviation (t distribution, 68% of the set) for 883 isolate sets characterized as FirstHip (yellow ellipse), and the remaining Hips (blue ellipse). 884 (E) We visualized the association between lineages that produced Hips versus slow growing 885 isolates (identified by the minimum growth rate of lineage isolates falling below 75% of the P. or YFP (Hip). Tagged isolates were cocultured and allowed to form biofilms in a flow-cell 976 model for 72 hours. Mixed biofilms were treated for 24 hours with ciprofloxacin (4 µg/ml). 977 
